. Author manuscript; available in PMC: 2010 Nov 15.

Published in final edited form as: Pediatr Infect Dis J. 2010 Oct;29(10):940–944. doi: 10.1097/INF.0b013e3181e2189d

TABLE 1.

Stage II Stavudine (d4T), lamivudine (3TC), and Nevirapine (NVP) Pharmacokinetic Parameters After Ingestion of GPO-VIR S7 or the Individual Liquid Formulations (Geometric Means and 90% CI) in HIV-infected Thai Children

	All Weight Groups (N=34)			GMR (90%CI)^‡ GPO-VIR S7/ Liquid
	GPO-VIR S7^*	Liquid^*	P^†	GMR (90%CI)^‡ GPO-VIR S7/ Liquid
d4T^§
AUC (μg h/mL)	1.54^¶ (1.42–1.67)	1.59^¶ (1.49–1.71)	0.25	0.97^¶ (0.92–1.02)
Cmax (μg/mL)	0.94^¶ (0.84–1.05)	0.87^¶ (0.79–0.95)	0.21	1.08^¶ (0.97–1.20)
3TC
AUC (μg hr/mL)	6.39^¶ (5.82–7.00)	4.52^¶ (4.14–4.94)	<0.0001 ^¶	1.41^¶ (1.30–1.53)
Cmax (μg/mL)	2.16^¶ (1.90–2.45)	1.35^¶ (1.23–1.50)	<0.0001 ^¶	1.59^¶ (1.39–1.82)
Cmin (μg/mL)	0.07^¶ (0.06–0.07)	0.07^¶ (0.06–0.07)	0.69	0.98^¶ (0.90–1.06)
NVP
AUC (μg h/mL)	74.06^¶ (65.62–83.60)	68.40^¶ (61.36–76.25)	0.005 ^¶	1.08^¶ (1.04–1.13)
Cmax (μg/mL)	7.80^¶ (7.01–8.67)	6.86^¶ (6.20–7.58)	<0.0001 ^¶	1.14^¶ (1.08–1.19)
Cmin (μg/mL)	4.68^¶ (4.04–5.43)	4.48^¶ (3.94–5.10)	0.21	1.05^¶ (0.99–1.11)

Reported values are geometric mean (90% CI).

^†

The p values are from paired t tests comparing the 2 formulations.

^‡

GMR (90%): Geometric mean ratio and 90% confidence interval.

^§

d4T Cmin was below lower limit of assay quantification (<0.025 μg/mL) over all weight groups.

^¶

P < 0.05 are bolded.